Sign In
Buy HZNP
$116.30
+0 (+0%)
At Close: Jan 04, 2024
Horizon (HZNP) Gets FDA Nod for Krystexxa's Label Expansion
01:08pm, Monday, 11'th Jul 2022
The FDA approves Horizon's (HZNP) sBLA for Krystexxa injection plus methotrexate to help people suffering from uncontrolled gout achieve a complete response to therapy.
Horizon Therapeutics plc to Release Second-Quarter 2022 Financial Results and Host Webcast on Aug. 3, 2022
08:00am, Thursday, 07'th Jul 2022
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its second-quarter 2022 financial results on Wednesday, Aug. 3, 2022. Following the announcement,
Horizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference
04:30pm, Monday, 06'th Jun 2022
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in June: Goldman Sachs 43rd Annual Global Health Care Con
Horizon (HZNP) Begins Enrollment in Alopecia Areata Study
12:47pm, Wednesday, 18'th May 2022
Horizon (HZNP) enrolls the first patient in a phase II study evaluating daxdilimab (HZN-7734) for the treatment of alopecia areata.
Horizon: For Those Who Dare
09:33am, Monday, 09'th May 2022
Horizon's inflammation segment is on fire in a not good way. The biopharmaceutical firm's orphan therapies segment presents another, far more interesting opportunity.
Horizon Therapeutics Public Limited Company (HZNP) CEO Tim Walbert on Q1 2022 Results - Earnings Call Transcript
10:02am, Wednesday, 04'th May 2022
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP ) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Tina Ventura - Senior Vice President, Chief Investor Relations O
Horizon Therapeutics (HZNP) Q1 Earnings and Revenues Beat Estimates
09:47am, Wednesday, 04'th May 2022
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 16.52% and 2.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
HZNP or TECH: Which Is the Better Value Stock Right Now?
12:48pm, Tuesday, 03'rd May 2022
HZNP vs. TECH: Which Stock Is the Better Value Option?
Horizon Therapeutics' Inebilizumab Scores European Approval For Spinal Cord Inflammation
01:25pm, Monday, 02'nd May 2022
The European Commission has approved Horizon Therapeutics plc's (NASDAQ: HZNP) Uplizna (inebilizumab) as monotherapy for neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 immu
Horizon Therapeutics (HZNP) Earnings Expected to Grow: Should You Buy?
04:50pm, Wednesday, 27'th Apr 2022
Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Horizon Therapeutics plc to Release First-Quarter 2022 Financial Results and Host Webcast on May 4, 2022
08:00am, Thursday, 14'th Apr 2022
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc to Release First-Quarter 2022 Financial Results and Host Webcast on May 4, 2022
Horizon Therapeutics (HZNP) Up 7.6% Since Last Earnings Report: Can It Continue?
12:47pm, Thursday, 31'st Mar 2022
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?
Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
11:31pm, Tuesday, 29'th Mar 2022
Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
Horizon Therapeutics Stock Shows Market Leadership; Earns 82 RS Rating
07:13pm, Tuesday, 08'th Mar 2022 Investor''s Business Daily
Horizon Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.
Horizon's (HZNP) sBLA for Krystexxa Gets FDA Priority Review
12:02pm, Tuesday, 08'th Mar 2022
The FDA grants priority review to Horizon's (HZNP) sBLA for Krystexxa plus methotrexate to treat people living with uncontrolled gout. A decision is due on Jul 7, 2022.
